Still, as involved as it is to blend the chemical
compounds of traditional pharmaceutical products, creating any
of a
class of medications known as biologics is
several orders
of magnitude more difficult.
We developed
several computational and machine learning methods to successfully identify behavioral patterns or signatures associated with different
classes of reference drugs, from which to predict the
class of novel
compounds (Brunner et al., 2012, Alexandrov et al., 2015), and more recently developed methods to allow us to compare animal models
of AD and its progression, and to identify (in silico) novel
compounds from our existing database
of thousands
of novel and reference
compounds with the potential to reverse the AD model behavioral profile.